These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

148 related items for PubMed ID: 11601159

  • 21. A comparative study of hypertonic saline, daily and alternate-day rhDNase in children with cystic fibrosis.
    Suri R, Wallis C, Bush A, Thompson S, Normand C, Flather M, Grieve R, Metcalfe C, Lees B.
    Health Technol Assess; 2002; 6(34):iii, 1-60. PubMed ID: 12583821
    [No Abstract] [Full Text] [Related]

  • 22. Effects of recombinant human DNase and hypertonic saline on airway inflammation in children with cystic fibrosis.
    Suri R, Marshall LJ, Wallis C, Metcalfe C, Bush A, Shute JK.
    Am J Respir Crit Care Med; 2002 Aug 01; 166(3):352-5. PubMed ID: 12153969
    [Abstract] [Full Text] [Related]

  • 23. Comparison of effects of 3 and 7% hypertonic saline nebulization on lung function in children with cystic fibrosis: a double-blind randomized, controlled trial.
    Gupta S, Ahmed F, Lodha R, Gupta YK, Kabra SK.
    J Trop Pediatr; 2012 Oct 01; 58(5):375-81. PubMed ID: 22374985
    [Abstract] [Full Text] [Related]

  • 24. Predicting response to rhDNase and hypertonic saline in children with cystic fibrosis.
    Suri R, Metcalfe C, Wallis C, Bush A.
    Pediatr Pulmonol; 2004 Apr 01; 37(4):305-10. PubMed ID: 15022126
    [Abstract] [Full Text] [Related]

  • 25. Nebulised hypertonic saline for cystic fibrosis.
    Wark PA, McDonald V, Jones AP.
    Cochrane Database Syst Rev; 2005 Jul 20; (3):CD001506. PubMed ID: 16034863
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Aerosolized deoxyribonuclease for cystic fibrosis.
    Med Lett Drugs Ther; 1994 Apr 15; 36(920):34-5. PubMed ID: 8145672
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. The use of pulmonary clearance medications in the acutely ill patient.
    Papacostas MF, Luckett P, Hupp S.
    Expert Rev Respir Med; 2017 Oct 15; 11(10):815-826. PubMed ID: 28780895
    [Abstract] [Full Text] [Related]

  • 33. Pharmacotherapy of impaired mucociliary clearance in non-CF pediatric lung disease. A review of the literature.
    Boogaard R, de Jongste JC, Merkus PJ.
    Pediatr Pulmonol; 2007 Nov 15; 42(11):989-1001. PubMed ID: 17902149
    [Abstract] [Full Text] [Related]

  • 34. Mucoactive agents for chronic, non-cystic fibrosis lung disease: A systematic review and meta-analysis.
    Tarrant BJ, Le Maitre C, Romero L, Steward R, Button BM, Thompson BR, Holland AE.
    Respirology; 2017 Aug 15; 22(6):1084-1092. PubMed ID: 28397992
    [Abstract] [Full Text] [Related]

  • 35. Retrospective review of the effects of rhDNase in children with cystic fibrosis.
    Davies J, Trindade MT, Wallis C, Rosenthal M, Crawford O, Bush A.
    Pediatr Pulmonol; 1997 Apr 15; 23(4):243-8. PubMed ID: 9141109
    [Abstract] [Full Text] [Related]

  • 36. The use of recombinant human dornase alfa in CF.
    Cox C.
    Paediatr Nurs; 1995 Nov 15; 7(9):29-31. PubMed ID: 8705343
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Nebulised hypertonic saline for cystic fibrosis.
    Wark PA, McDonald V.
    Cochrane Database Syst Rev; 2003 Nov 15; (1):CD001506. PubMed ID: 12535409
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.